• About Us
    • About Neurocrine
    • Leadership Team
      • Management Team
      • Board of Directors
    • News & Events
    • Webcasts & Presentations
    • Contact Us
  • Patients & Families
    • Overview
    • Tardive Dyskinesia
    • Tourette Syndrome
    • Endometriosis
    • Uterine Fibroids
    • Congenital Adrenal Hyperplasia
  • Pipeline
    • Overview
    • Elagolix
      GnRH Antagonist
      • Endometriosis
        • Clinical Trials
      • Uterine Fibroids
        • Clinical Trials
    • NBI-98854
      VMAT2 Inhibitor
      • Tardive Dyskinesia
        • Clinical Trials
      • Tourette Syndrome
        • Clinical Trials
    • NBI-77860
      CRF1 Antagonist
      • Congential Adrenal Hyperplasia
        • Clinical Trials
    • Additional Pipeline Programs
  • Careers
    • Overview
    • Benefits
  • Investors
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Shareholder Contacts
    • Fundamentals
    • Partners/Collaborators
    • Annual Meeting
    • Online Annual Reports
    • Ownership
    • Email Alerts
    • Corporate Governance
    • Event Calendar
    • Webcasts & Presentations
  • Contact Us

SEC Filings

Form SC 13G/A
NEUROCRINE BIOSCIENCES INC filed this Form SC 13G/A on 02/11/2019
Document Outline
Entire Document (31.8 KB)
Subdocument 1 - SC 13G/A
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A

Investors

  • Press Releases
  • Stock Quote
  • SEC Filings
  • Shareholder Contacts
  • Fundamentals
  • Partners/Collaborators
  • Annual Meeting
  • Online Annual Reports
  • Ownership
  • Email Alerts
  • Corporate Governance
  • Event Calendar
  • Webcasts & Presentations

Investor Toolkit

Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
  • ©2016 Neurocrine Biosciences, Inc.
  • All Rights Reserved.
  • Privacy Policy
  • Terms & Conditions
  • Sitemap
  • CP-NBI-US-0001 08/16